

GYNECOLOGY

Pain and activity after vaginal reconstructive surgery for pelvic organ prolapse and stress urinary incontinence



Matthew D. Barber, MD, MHS; Linda Brubaker, MD, MS; Ingrid Nygaard, MD, MS; Clifford Y. Wai, MD; Keisha Y. Dyer, MD MPH; David Ellington, MD; Amaanti Sridhar, MS; Marie G. Gantz, PhD; for the NICHD Pelvic Floor Disorders Network

BACKGROUND: Little is known about short- and long-term pain and functional activity after surgery for pelvic organ prolapse.

OBJECTIVE: The objectives of the study were to describe postoperative pain and functional activity after transvaginal native tissue reconstructive surgery with apical suspension and retropubic synthetic midurethral sling and to compare these outcomes between patients receiving 2 common transvaginal prolapse repairs, uterosacral ligament, and sacrospinous ligament vaginal vault suspension.

STUDY DESIGN: This planned secondary analysis of a 2 × 2 factorial randomized trial included 374 women randomized to receive uterosacral (n = 188) or sacrospinous (n = 186) vaginal vault suspension to treat both stages 2–4 apical vaginal prolapse and stress urinary incontinence between 2008 and 2013 at 9 medical centers. Participants were also randomized to receive perioperative pelvic muscle therapy or usual care. All patients received transvaginal native tissue repairs and a midurethral sling. Participants completed the Surgical Pain Scales (0–10 numeric rating scales; higher scores = greater pain) and Activity Assessment Scale (0–100; higher score = higher activity) prior to surgery and at 2 weeks, 4–6 weeks, and 3 months postoperatively. The MOS 36-item Short-Form Health Survey was completed at baseline and 6, 12, and 24 months after surgery; the bodily pain, physical functioning, and role–physical subscales were used for this analysis (higher scores = less disability). Self-reported pain medication use was also collected.

RESULTS: Before surgery, average pain at rest and during normal activity were (adjusted mean ± SE) 2.24 ± 0.23 and 2.76 ± 0.25; both increased slightly from baseline at 2 weeks (+0.65, *P* = .004, and +0.74, *P* = .007, respectively) and then decreased below baseline at 3 months (−0.87 and −1.14, respectively, *P* < .001), with no differences between surgical groups. Pain during exercise/strenuous activity and

worst pain decreased below baseline levels at 4–6 weeks (−1.26, *P* = .014, and −0.95, *P* = .002) and 3 months (−1.97 and −1.50, *P* < .001) without differences between surgical groups. Functional activity as measured by the Activity Assessment Scale improved from baseline at 4–6 weeks (+9.24, *P* < .001) and 3 months (+13.79, *P* < .001). The MOS 36-item Short-Form Health Survey Bodily Pain, Physical Functioning, and Role–Physical Scales demonstrated significant improvements from baseline at 6, 12, and 24 months (24 months: +5.62, +5.79, and +4.72, respectively, *P* < .001 for each) with no differences between groups. Use of narcotic pain medications was reported by 14.3% of participants prior to surgery and 53.7% at 2 and 26.1% at 4–6 weeks postoperatively; thereafter use was similar to baseline rates until 24 months when it decreased to 6.8%. Use of nonnarcotic pain medication was reported by 48.1% of participants prior to surgery, 68.7% at 2 weeks, and similar to baseline at 3 months; thereafter use dropped steadily to 26.6% at 2 years. Uterosacral ligament suspension resulted in less new or worsening buttock pain than sacrospinous suspension at 4–6 weeks postoperatively (4.6% vs 10.5%, *P* = .043) but no difference in groin or thigh pain.

CONCLUSION: Pain and functional activity improve for up to 2 years after native tissue reconstructive surgery with uterosacral or sacrospinous vaginal vault suspension and midurethral sling for stages 2–4 pelvic organ prolapse. On average, immediate postoperative pain is low and improves to below baseline levels by 4–6 weeks.

Key words: functional activity, pelvic floor disorders, pelvic organ prolapse, postoperative pain, sacrospinous ligament fixation, stress urinary incontinence, uterosacral ligament suspension, vaginal reconstructive surgery

In recent years, there has been increasing emphasis on enhancing recovery after surgery, with goals of improving patient postoperative experience and return of function. Pelvic floor disorders are common conditions for which 1 in 5 women in the United

States will undergo surgery by age 80 years.¹

With greater than 300,000 surgical procedures for pelvic organ prolapse performed each year, urogynecological patient outcomes are of unique interest in women's health care.² However, little is known about postoperative pain or activity for these procedures.

While surgery for pelvic organ prolapse can be performed using multiple approaches including robotic, laparoscopic, and vaginal approaches with and without mesh augmentation, 80–90% are performed transvaginally without mesh (ie, transvaginal native tissue repair).^{2–5} The 2 most common native

tissue procedures for correcting apical prolapse are the sacrospinous ligament fixation (SSLF) and the uterosacral ligament suspension (ULS).⁶

Postoperative pain, namely gluteal and posterior thigh pain, is well described for women undergoing SSLF and generally resolves within 6 weeks for the majority of patients.^{7,8} Postoperative neuropathic pain has also been described for patients undergoing ULS; however, these reports are primarily focused on pain as an immediate postoperative complication but not on outcomes potentially related to the pain, such as return to activity, pain medication use, and functional status.^{9,10}

Cite this article as: Barber MD, Brubaker L, Nygaard I, et al. Pain and activity after vaginal reconstructive surgery for pelvic organ prolapse and stress urinary incontinence. *Am J Obstet Gynecol* 2019;221:233.e1-16.

0002-9378/\$36.00

© 2019 Elsevier Inc. All rights reserved.

<https://doi.org/10.1016/j.ajog.2019.06.004>

➤ Related editorial, page 177

AJOG at a Glance

Why was this study conducted?

Little is known about both short- and long-term pain and functional activity after transvaginal surgery for pelvic organ prolapse.

Key findings

In women undergoing 2 types of commonly performed transvaginal, native-tissue prolapse repairs with concomitant retropubic midurethral sling, pain and functional activity improve for up to 2 years. On average, immediate postoperative pain is low and improves to below baseline levels by 4–6 weeks.

What does this add to what is known?

Clinicians can use the information from this study to counsel women about pain and functional activity for the first 2 years after transvaginal surgery for prolapse.

Beyond these reported adverse events, there are few data available on the short- and long-term pain and functional activity after surgery for pelvic organ prolapse, limiting the ability of clinicians to fully counsel their patients.

The objective of this planned secondary analysis is to describe postoperative pain and functional activity after transvaginal native tissue reconstructive surgery with apical suspension and to compare these outcomes between patients randomized to receive ULS or SSLF.

Materials and Methods

This is a planned analysis of secondary outcomes of the Operations and Pelvic Muscle Training in the Management of Apical Support Loss (OPTIMAL) trial, a multicenter clinical trial conducted by the Eunice Kennedy Shriver National Institute for Childhood Health and Human Development Pelvic Floor Disorders Network at 9 clinical sites.

Details of this study have been previously published.^{8,11} Briefly, the Operations and Pelvic Muscle Training in the Management of Apical Support Loss trial was 2 × 2 factorial designed trial comparing 2 native tissue vaginal prolapse apical suspensions (ULS vs SSLF) with midurethral sling surgery in women with ≥stage 2 uterine or vaginal prolapse and stress urinary incontinence and perioperative behavioral therapy with pelvic floor muscle training (PMT) vs usual perioperative care.

The study had 2 primary aims: (1) to compare surgical outcomes of SSLF with

ULS 24 months after vaginal surgery for apical or uterine prolapse and stress incontinence and (2) to evaluate the impact of a perioperative behavioral-pelvic muscle therapy program on urinary and prolapse outcomes. Each clinical site's institutional review board approved the study, and all participants completed a research-informed consent process.

Each enrolled patient first underwent a 1:1 perioperative behavioral and pelvic muscle therapy vs usual care randomization followed by a second 1:1 surgical randomization. All participants received a transvaginal native-tissue (nonmesh) pelvic organ prolapse repair and a synthetic mesh retropubic midurethral sling (tension-free vaginal tape; Ethicon, Somerville, NJ).

Participants randomized to PMT received an individualized program that included 1 visit 2–4 weeks prior to surgery and 4 postoperative visits (2, 4–6, 8, and 12 weeks after surgery). Each participant received a standardized postoperative instruction sheet encouraging them to resume light activities including stretching, walking, climbing stairs, cooking, and clerical work as soon as they felt comfortable with the activity while asking them to refrain from activities that caused a feeling of pressure in the pelvic or vaginal area, including heavy lifting or vigorous exercise for 6 weeks after surgery.

Participants were masked to surgical treatment assignment and underwent standardized evaluations by masked assessors at baseline, 2 and 4–6 weeks, 3, 6,

12, and 24 months including administration of validated patient-reported outcome measures. The Surgical Pain Scales (SPS) and Activity Assessment Scale (AAS) were administered at baseline, 2 weeks, 4–6 weeks, and 3 months after surgery.^{12,13}

The SPS were designed for use in the perioperative period and assess pain at rest, pain during normal activities, pain during strenuous activities/exercise, and pain unpleasantness/worst pain using 4 numerical rating scales (0–10) with higher scores indicating worse pain.¹³

The AAS is a measure of functional activity also designed for use in the perioperative period.¹² The AAS includes 13 items covering a broad sample of sedentary, movement-related, and graded-intensity physical activities. Respondents were asked to rate the degree of difficulty performing each of these activities in the previous 24 hours on a 5-point scale from no difficulty to not able to do it. The response item, did not perform for other reasons, is also included but not scored.

The AAS has 3 subscales: sedentary activities, ambulatory activities, and work/exercise activities. The AAS total and subscale scores are transformed to produce a range of 0 to 100, with higher values indicating greater functional activity.

Subjects completed the MOS 36-item Short-Form Health Survey (SF-36) at baseline, 6, 12, and 24 months after surgery.¹⁴ For this analysis, we assessed the SF-36 bodily pain, physical functioning, and role limitations-physical subscales. Each subscale is scored 0–100, with higher scores indicating better health and is norm based so that 50 is the population mean and 10 is the population standard deviation.

Patients also self-reported medication use at baseline and each follow-up visit. For this analysis, pain medication was classified into 2 groups: narcotic and nonnarcotic (ie, nonsteroidal antiinflammatory drugs and acetaminophen). Other medications that may modify pain response such as gabapentin, benzodiazepines, or steroids were not included in this classification. At 2 and 4–6 weeks after surgery, participants were asked whether they developed any new or


TABLE 1
Surgical pain scales from baseline to 3 months after surgery modeling outcome as change from baseline^a

Variable	Time frame	All surgical treatments (n = 371)		ULS surgical treatment (n = 185)		SSLF surgical treatment (n = 186)		Surgical treatment difference	
		Adjusted mean (SE, n)	Adjusted Pvalue ^b	Adjusted mean (SE, n)	Adjusted Pvalue ^b	Adjusted mean (SE, n)	Adjusted Pvalue ^b	Adjusted mean difference (95% CI) ^c	Adjusted Pvalue ^c
Pain at rest^d									
	Baseline	2.24 (0.23, 369)	—	2.20 (0.25, 184)	—	2.28 (0.26, 185)	—	−0.08 (−0.53, 0.36)	.711
	2 week change	0.65 (0.23, 354)	.004	0.57 (0.26, 177)	.027	0.72 (0.26, 177)	.006	−0.15 (−0.65, 0.35)	.551
	4–6 week change	−0.41 (0.23, 362)	.068	−0.53 (0.26, 181)	.039	−0.29 (0.26, 181)	.259	−0.24 (−0.73, 0.26)	.347
	3 month change	−0.87 (0.23, 340)	< .001	−0.93 (0.26, 168)	< .001	−0.81 (0.26, 172)	.002	−0.12 (−0.63, 0.39)	.644
Pain during normal activities^e									
	Baseline	2.76 (0.25, 368)	—	2.66 (0.28, 183)	—	2.86 (0.28, 185)	—	−0.20 (−0.69, 0.30)	.435
	2 week change	0.74 (0.27, 353)	.007	0.63 (0.31, 176)	.042	0.85 (0.31, 177)	.006	−0.23 (−0.81, 0.35)	.440
	4–6 week change	−0.46 (0.27, 362)	.087	−0.60 (0.31, 180)	.052	−0.33 (0.31, 182)	.287	−0.27 (−0.84, 0.31)	.362
	3 month change	−1.14 (0.27, 338)	< .001	−1.20 (0.31, 167)	< .001	−1.08 (0.31, 171)	.001	−0.12 (−0.71, 0.47)	.686
Pain during exercise, strenuous activities									
	Baseline	3.71 (0.42, 211)	—	3.66 (0.47, 94)	—	3.76 (0.45, 117)	—	−0.10 (−0.87, 0.67)	.794
	2 week change	−0.36 (0.57, 42)	.527	−0.47 (0.74, 17)	.527	−0.26 (0.65, 25)	.693	−0.21 (−1.78, 1.36)	.793
	4–6 week change	−1.26 (0.51, 83)	.014	−1.38 (0.62, 35)	.028	−1.14 (0.56, 48)	.043	−0.23 (−1.45, 0.98)	.703
	3 month change	−1.97 (0.48, 132)	< .001	−1.74 (0.55, 60)	.002	−2.20 (0.54, 72)	< .001	0.46 (−0.56, 1.48)	.376
Worst pain^f									
	Baseline	2.98 (0.29, 368)	—	2.91 (0.32, 183)	—	3.05 (0.32, 185)	—	−0.14 (−0.70, 0.42)	.620
	2 week change	0.42 (0.30, 350)	.168	0.23 (0.34, 175)	.506	0.61 (0.35, 175)	.082	−0.38 (−1.04, 0.28)	.256
	4–6 week change	−0.95 (0.30, 361)	.002	−1.08 (0.34, 179)	.002	−0.83 (0.35, 182)	.017	−0.25 (−0.90, 0.40)	.449
	3 month change	−1.50 (0.30, 338)	< .001	−1.66 (0.35, 166)	< .001	−1.35 (0.35, 172)	< .001	−0.32 (−0.98, 0.35)	.350

SSLF, sacrospinous ligament fixation; ULS, uterosacral ligament suspension.

^a The analyses for each outcome of interest were performed on the modified intent-to-treat population, which includes all participants who were eligible, gave consent, were randomized to both the PMT and surgical interventions, and for whom the outcome was assessed (ie, nonmissing). For analyses assessing each outcome's change from baseline to a follow-up visit, all adjusted means, mean differences, SEs, 95% confidence intervals, and P values for outcomes were obtained from general linear models adjusting for randomized surgical intervention, randomized PMT intervention, visit, interaction between visit and randomized surgical intervention, interaction between visit and randomized PMT intervention, and 3-way interaction between visit and randomized surgical intervention and randomized PMT intervention, concomitant hysterectomy, age at surgical randomization, race (white, black, other), ethnicity, public insurance, and private insurance while controlling for a random surgeon effect (if found statistically significant) and repeated subject visits. All tests were conducted at a significance level of $P = .05$; ^b This adjusted P value corresponds to the test assessing whether there was a statistically significant change from baseline; ^c This adjusted P value corresponds to the test assessing whether there was a statistically significant difference in the outcome between the 2 surgical treatments; ^d The effect of surgery varies across the PMT groups and across visits ($P = .006$). See Table 2 for the effect of randomized surgical intervention within the PMT and non-PMT groups; ^e The effect of surgery varies across the PMT groups and across visits ($P = .001$). See Table 2 for the effect of randomized surgical intervention within the PMT and non-PMT groups; ^f The effect of surgery varies across the PMT groups and across visits ($P = .001$). See Table 2 for the effect of randomized surgical intervention within the PMT and non-PMT groups.

Barber et al. Pain and activity after prolapse surgery. Am J Obstet Gynecol 2019.

FIGURE 1
Surgical pain scales, baseline to 3 months after surgery (unadjusted)**A**, Pain at rest. **B**, Pain during normal activities. **C**, Pain during exercise, strenuous work, or lifting objects. **D**, Worst pain.Barber et al. Pain and activity after prolapse surgery. *Am J Obstet Gynecol* 2019.

worsening pain in the leg/thigh, buttock, or groin since surgery including severity (mild, moderate, or severe) and need for additional narcotic pain medications or other therapies.

Statistical analyses were conducted on a modified intent-to-treat (mITT) population that included all participants who were randomized to both the PMT and surgical interventions and for whom the outcome was assessed. Baseline SPS, AAS, and subscales and SF-36 scores were compared between surgical treatment groups using general linear models, and postoperative changes from baseline were compared between groups using general linear mixed models.

All models controlled for PMT treatment assignment, interaction between surgery and PMT, concomitant hysterectomy, age at randomization, race, ethnicity, insurance status, and study

visit; interactions between surgical and PMT assignments and visit were included in the general linear mixed models. The correlation between repeated measures on the same participant was modeled using a compound symmetry covariance structure.

Because the surgical randomization was stratified by surgeon, surgeon was evaluated as a random effect and retained in the model if statistically significant at an alpha level of 0.05. If the interaction between surgical and PMT groups was statistically significant at an alpha level of 0.05, the surgical groups were compared within each PMT group.

Use of narcotic and nonnarcotic pain medications was modeled using comparable generalized linear mixed models with a logit link. New or worsening pain, moderate or severe pain, pain requiring narcotic pain medications, and pain


requiring other treatment were compared between surgical groups using Fisher exact tests and unadjusted odds ratios (ORs) and 95% confidence intervals (CIs).

Results

Overall, average pain scores (adjusted mean \pm SE) at rest and during normal activity before surgery were 2.24 ± 0.23 (minimum to maximum, 0–10) and 2.76 ± 0.25 (minimum to maximum 0–9), respectively (Table 1 and Figure 1). Compared with baseline values, both scores increased slightly at 2 weeks after surgery (rest, $+0.65$, $P = .004$; normal activity, $+0.74$, $P = .007$) and then decreased below baseline at 3 months (rest, -0.87 , $P < .001$; normal activity, -1.14 , $P < .001$).

Pain experienced during exercise/strenuous activity (performed postoperatively by a minority of participants;

FIGURE 2
Difference in Surgical Pain Scale scores between surgical interventions



Difference in Surgical Pain Scale scores between surgical interventions, from baseline to 3 months after surgery, modeling outcome as change from baseline is shown. (The analyses for each outcome of interest were performed on the modified intent to treat population, which includes all participants who were eligible, gave consent, were randomized to both the pelvic floor muscle training [PMT] and surgical interventions, and for whom the outcome was assessed (ie, nonmissing). For analyses assessing each outcome's change from baseline to a follow-up visit, all adjusted means, mean differences, SEs, 95% confidence intervals, and P values for outcomes were obtained from general linear models adjusting for randomized surgical intervention, randomized PMT intervention, visit, interaction between visit and randomized surgical intervention, interaction between visit and randomized PMT intervention, and 3-way interaction between visit and randomized surgical intervention and randomized PMT intervention, concomitant hysterectomy, age at surgical randomization, race [white, black, other], ethnicity, public insurance, and private insurance while controlling for a random surgeon effect (if found statistically significant) and repeated subject visits. All tests were conducted at a significance level of $P = .05$.) **A**, Pain at rest difference between surgical interventions across visits. **B**, Pain during normal activities difference between surgical interventions across visits. **C**, Pain during exercise and strenuous activities difference between surgical interventions across visits. **D**, Worst pain difference between surgical interventions across visits.

Barber et al. Pain and activity after prolapse surgery. Am J Obstet Gynecol 2019.

see Table 1) decreased below baseline levels at 4–6 weeks after surgery (-1.26 , $P = .014$), with this reduction persisting at 3 months (-1.97 , $P < .001$). Worst pain also decreased from baseline at 4–6 weeks (-0.95 , $P = .002$) and at 3 months (-1.50 , $P < .001$). The change in pain scores for each activity and time point spanned values of -10 to $+10$ (data not shown).

Baseline pain scores were similar between patients who received ULS and those who underwent SSLF: at rest (2.20 ± 0.25 vs 2.28 ± 0.26 , $P = .711$) and with normal activity (2.66 ± 0.28 vs $2.86 \pm$

0.28 , $P = .435$). There were no statistically significant differences between the 2 surgical groups in changes in pain scores at rest, with normal activity, during exercise/strenuous activity or for worst pain experienced at 2 weeks, 4–6 weeks, or 3 months after surgery (Table 1 and Figure 2).

In the PMT group, pain at rest demonstrated a statistically significant improvement at 3 months in the ULS but not the SSLF group (Table 2). Improvement in pain during normal activities and worst pain was also noted at 3 months after surgery for both

surgeries, with greater improvements in the ULS group compared with SSLF (Table 2). Among patients randomized to usual postoperative care (non-PMT), pain at rest, pain during normal activities, and worst pain improved at 3 months, with greater improvements in the SSLF group for pain at rest (Table 2).

Functional activity, as measured by the overall scores on the AAS, improved in the total study population at 4–6 weeks ($+9.24 \pm 1.92$, $P < .001$), and further improved at 3 months ($+13.79 \pm 1.94$, $P < .001$) after surgery,

TABLE 2
Surgical pain scales from baseline to 3 months after surgery in PMT and non-PMT groups modeling outcome as change from baseline^a

Variable	Time frame	PMT group					Non-PMT group						
		ULS surgical treatment (n = 90)		SSLF surgical treatment (n = 95)		Surgical treatment difference	ULS surgical treatment (n = 95)		SSLF surgical treatment (n = 91)		Surgical treatment difference		
		Adjusted mean (SE, n)	Adjusted Pvalue ^b	Adjusted mean (SE, n)	Adjusted Pvalue ^b	Adjusted mean difference (95% CI) ^c	Adjusted Pvalue ^c	Adjusted mean (SE, n)	Adjusted Pvalue ^b	Adjusted mean (SE, n)	Adjusted Pvalue ^b	Adjusted mean difference (95% CI) ^c	Adjusted Pvalue ^c
Pain at rest													
	Baseline	2.12 (0.30, 90)	—	2.60 (0.30, 95)	—	−0.48 (−1.11, 0.14)	.129	2.28 (0.30, 94)	—	1.96 (0.31, 90)	—	0.32 (−0.31, 0.95)	.322
	2 week change	0.46 (0.31, 86)	.142	0.52 (0.31, 90)	.099	−0.06 (−0.76, 0.65)	.872	0.68 (0.32, 91)	.032	0.93 (0.32, 87)	.004	−0.25 (−0.95, 0.46)	.496
	4–6 week change	−0.63 (0.31, 89)	.043	−0.76 (0.31, 93)	.015	0.12 (−0.57, 0.82)	.726	−0.43 (0.32, 92)	.174	0.17 (0.32, 88)	.597	−0.60 (−1.31, 0.10)	.095
	3 month change	−0.60 (0.32, 83)	.057	−1.37 (0.31, 87)	< .001	0.77 (0.05, 1.48)	.036	−1.26 (0.32, 85)	< .001	−0.26 (0.32, 85)	.423	−1.00 (−1.72, −0.29)	.006
Pain during normal activities													
	Baseline	2.55 (0.33, 90)	—	2.99 (0.33, 95)	—	−0.44 (−1.14, 0.25)	.208	2.78 (0.34, 93)	—	2.72 (0.34, 90)	—	0.05 (−0.65, 0.75)	.880
	2 week change	0.48 (0.37, 86)	.192	0.78 (0.37, 90)	.035	−0.30 (−1.12, 0.52)	.472	0.77 (0.38, 90)	.041	0.93 (0.38, 87)	.015	−0.16 (−0.98, 0.67)	.710
	4–6 week change	−0.59 (0.37, 89)	.110	−0.60 (0.37, 94)	.101	0.01 (−0.80, 0.83)	.972	−0.61 (0.38, 91)	.107	−0.06 (0.38, 88)	.878	−0.55 (−1.37, 0.27)	.189
	3 month change	−0.74 (0.37, 83)	.046	−1.52 (0.37, 87)	< .001	0.77 (−0.06, 1.60)	.067	−1.65 (0.38, 84)	< .001	−0.64 (0.38, 84)	.096	−1.01 (−1.85, −0.18)	.017

Barber et al. Pain and activity after prolapse surgery. Am J Obstet Gynecol 2019.

(continued)

TABLE 2
Surgical pain scales from baseline to 3 months after surgery in PMT and non-PMT groups modeling outcome as change from baseline^a (continued)

Variable Time frame	PMT group			Non-PMT group			Surgical treatment difference					
	ULS surgical treatment (n = 90)			SSLF surgical treatment (n = 95)			ULS surgical treatment (n = 95)			SSLF surgical treatment (n = 91)		
	Adjusted mean (SE, n)	Adjusted P value ^b	Adjusted P value ^b	Adjusted mean (SE, n)	Adjusted P value ^b	Adjusted P value ^b	Adjusted mean (SE, n)	Adjusted P value ^b	Adjusted mean (SE, n)	Adjusted P value ^b	Adjusted P value ^b	
Worst pain												
Baseline	2.72 (0.37, 90)	—	—	3.14 (0.37, 95)	—	.296	3.09 (0.38, 93)	—	2.96 (0.39, 90)	—	.735	
2 week change	0.13 (0.41, 85)	.755	.132	0.63 (0.42, 89)	.132	.294	0.33 (0.42, 90)	.438	0.59 (0.43, 86)	.167	.579	
4–6 week change	−0.88 (0.41, 89)	.034	.003	−1.25 (0.41, 94)	.003	.430	−1.28 (0.42, 90)	.003	−0.41 (0.42, 88)	.338	.066	
3 month change	−1.05 (0.42, 82)	.013	<.001	−1.72 (0.42, 87)	<.001	.162	−2.27 (0.43, 84)	<.001	−0.97 (0.43, 85)	.024	.007	

CI, confidence interval; PMT, pelvic floor muscle training; SSLF, sacrospinous ligament fixation; ULS, uterosacral ligament suspension.

^a The analyses for each outcome of interest were performed on the modified intent-to-treat population, which includes all participants who were eligible, gave consent, were randomized to both the PMT and surgical interventions, and for whom the outcome was assessed (ie, not missing). For analyses assessing each outcome's change from baseline to a follow-up visit, all adjusted means, mean differences, SEs, 95% confidence intervals, and P values for outcomes were obtained from general linear models adjusting for randomized surgical intervention, randomized PMT intervention, visit, interaction between visit and randomized surgical intervention, interaction between visit and randomized surgical intervention and randomized PMT intervention, concomitant hysterectomy, age at surgical randomization, race (white, black, other), ethnicity, public insurance, and private insurance while controlling for a random surgeon effect (if found statistically significant) and repeated subject visits. All tests were conducted at a significance level of $P = .05$.^b This adjusted P value corresponds to the test assessing whether there was a statistically significant difference in the outcome between the 2 surgical treatments.

Barber et al. Pain and activity after prolapse surgery. Am J Obstet Gynecol 2019.

compared with baseline (Table 3). Compared with presurgery levels, there was a transient decrease in sedentary activity at 2 weeks. Scores increased at 4–6 weeks ($+2.27 \pm 0.70$, $P = .001$) and at 3 months ($+3.68 \pm 0.71$, $P < .001$). Scores for the 2 remaining subscales (ambulatory and work/exercise) also improved at 4–6 weeks ($+2.49 \pm 0.62$, $P < .001$; $+4.64 \pm 1.09$, $P < .001$, respectively) and at 3 months ($+3.65 \pm 0.63$, $P < .001$; $+7.11 \pm 1.10$, $P < .001$, respectively) (Table 3 and Figure 3).

There were no significant differences in the overall AAS scores before surgery between patients randomized to ULS and SSLF (78.10 ± 1.99 vs 77.96 ± 2.00 , $P = .931$). Aside from an overall and sedentary subscale score indicating less activity in the SSLF group at 2 weeks, there were no significant differences in any of the subsequent time points (4–6 weeks or 3 months) in either the overall or any subscale score between surgeries (Table 3).

For patients assigned to PMT, overall AAS scores improved at 4–6 weeks and were maintained at 3 months. Scores for the sedentary activities subscale also demonstrated improvement 3 months postoperatively, with more improvement in the ULS than the SSLF group. Patients in the non-PMT group had improved scores for overall AAS and for the sedentary activities subscale, which persisted at 3 months after surgery, without differences between the surgical groups (Table 4).

The SF-36 Bodily Pain, Physical Functioning and Role–Physical Scales all demonstrated significant improvements from baseline at 6 months ($+6.72 \pm 1.34$, $+5.60 \pm 1.11$ and $+4.70 \pm 1.11$, respectively, $P < .001$ for each), 12 months ($+6.80 \pm 1.34$, $+5.96 \pm 1.11$ and $+5.26 \pm 1.11$, respectively, $P < .001$ for each), and 24 months ($+5.62 \pm 1.35$, $+5.79 \pm 1.12$ and $+4.72 \pm 1.12$, respectively, $P < .001$ for each). No significant differences between ULS and SSLF surgery groups were noted at any time point after surgery (Table 5 and Figure 4).

Groin and leg/thigh pain were reported at 2 weeks by 8.7% and 8.5%, respectively, and at 4–6 weeks by 3.8%

TABLE 3
Activity assessment scale changes from baseline to 3 months after surgery modeling outcome as change from baseline^a

Variable	Time frame	Statistic	All surgical treatments (n = 373)		ULS surgical treatment (n = 187)		SSLF surgical treatment (n = 186)		Surgical treatment difference	
			Estimate	Adjusted Pvalue ^b	Estimate	Adjusted Pvalue ^b	Estimate	Adjusted Pvalue ^b	Adjusted mean difference (95% CI) ^c	Adjusted Pvalue ^c
Overall AAS Score^d										
	Baseline	Adjusted Mean (SE, N)	78.03 (1.80, 370)	—	78.10 (1.99, 185)	—	77.96 (2.00, 185)	—	0.15 (−3.26, 3.56)	0.931
	Baseline	Min to Max	25 to 100		25 to 100		25 to 100			
	2 week change	Adjusted mean (SE, n)	−0.30 (1.93, 344)	.878	2.48 (2.19, 170)	.258	−3.07 (2.20, 174)	.163	5.55 (1.47, 9.63)	.008
	2 week change	Min to max	−77 to 73		−74 to 73		−77 to 54			
	4–6 week change	Adjusted mean (SE, n)	9.24 (1.92, 364)	< .001	9.73 (2.17, 182)	< .001	8.76 (2.18, 182)	< .001	0.97 (−3.06, 4.99)	.638
	4-6 week change	Min to max	−53 to 73		−51 to 73		−53 to 54			
	3 month change	Adjusted mean (SE, n)	13.79 (1.94, 332)	< .001	14.11 (2.20, 168)	< .001	13.47 (2.22, 164)	< .001	0.64 (−3.49, 4.76)	.762
	3 month change	Min to max	−42 to 63		−42 to 63		−42 to 58			
Sedentary Activities Scale^e										
	Baseline	Adjusted Mean (SE, N)	30.41 (0.64, 370)	—	30.35 (0.71, 185)	—	30.47 (0.71, 185)	—	−0.12 (−1.33, 1.09)	.845
	Baseline	Min to Max	9 to 36		9 to 36		9 to 36			
	2 week change	Adjusted Mean (SE, N)	−1.79 (0.70, 355)	.012	−0.48 (0.80, 177)	.547	−3.10 (0.80, 178)	< .001	2.62 (1.13, 4.10)	.001
	2 week change	Min to Max	−30 to 27		−30 to 27		−25 to 18			
	4–6 week change	Adjusted Mean (SE, N)	2.27 (0.70, 365)	.001	2.54 (0.80, 182)	.002	2.00 (0.80, 183)	.013	0.54 (−0.94, 2.02)	.472
	4–6 week change	Min to max	−20 to 27		−18 to 27		−20 to 23			
	3 month change	Adjusted mean (SE, n)	3.68 (0.71, 336)	< .001	4.00 (0.81, 168)	< .001	3.37 (0.81, 168)	< .001	0.62 (−0.89, 2.14)	.418
	3 month change	Min to max	−18 to 27		−18 to 27		−18 to 23			

Barber et al. Pain and activity after prolapse surgery. Am J Obstet Gynecol 2019.

(continued)

TABLE 3


Activity assessment scale changes from baseline to 3 months after surgery modeling outcome as change from baseline^a (continued)

Variable	Time frame	Statistic	All surgical treatments (n = 373)		ULS surgical treatment (n = 187)		SSLF surgical treatment (n = 186)		Surgical treatment difference	
			Estimate	Adjusted Pvalue ^b	Estimate	Adjusted Pvalue ^b	Estimate	Adjusted Pvalue ^b	Adjusted mean difference (95% CI) ^c	Adjusted Pvalue ^c
Ambulatory Activities Scale										
	Baseline	Adjusted mean (SE, n)	21.47 (0.58, 371)	—	21.58 (0.65, 185)	—	21.36 (0.65, 186)	—	0.22 (−0.89, 1.32)	.701
	Baseline	Min to max	2 to 27		2 to 27		5 to 27			
	2 week change	Adjusted mean (SE, n)	0.64 (0.62, 355)	.303	1.27 (0.70, 176)	.072	0.01 (0.71, 179)	.986	1.26 (−0.05, 2.57)	.059
	2 week change	Min to max	−20 to 25		−20 to 25		−20 to 20			
	4–6 week change	Adjusted mean (SE, n)	2.49 (0.62, 366)	< .001	2.63 (0.70, 182)	< .001	2.35 (0.71, 184)	.001	0.28 (−1.02, 1.57)	.675
	4–6 week change	Min to max	−20 to 25		−20 to 25		−18 to 20			
	3 month change	Adjusted mean (SE, n)	3.65 (0.63, 337)	< .001	3.58 (0.71, 168)	< .001	3.72 (0.71, 169)	< .001	−0.14 (−1.46, 1.19)	.841
	3 month change	Min to max	−16 to 23		−16 to 18		−14 to 23			
Work/Exercise Activities Scale										
	Baseline	Adjusted mean (SE, n)	24.76 (0.97, 369)	—	24.93 (1.08, 184)	—	24.59 (1.08, 185)	—	0.34 (−1.50, 2.18)	.715
	Baseline	Min to max	2 to 36		3 to 36		2 to 36			
	2 week change	Adjusted mean (SE, n)	0.42 (1.11, 310)	.703	1.43 (1.26, 154)	.257	−0.58 (1.27, 156)	.645	2.01 (−0.40, 4.43)	.102
	2 week change	Min to max	−36 to 32		−36 to 23		−36 to 32			
	4–6 week change	Adjusted mean (SE, n)	4.64 (1.09, 352)	< .001	4.48 (1.24, 177)	< .001	4.81 (1.25, 175)	< .001	−0.33 (−2.66, 1.99)	.778
	4–6 week change	Min to max	−32 to 30		−27 to 27		−32 to 30			
	3 month change	Adjusted mean (SE, n)	7.11 (1.10, 329)	< .001	7.05 (1.25, 167)	< .001	7.17 (1.26, 162)	< .001	−0.11 (−2.49, 2.26)	.925
	3 month change	Min to max	−25 to 32		−18 to 27		−25 to 32			

AAS, Ambulatory Activities Scale; CI, confidence interval; SSLF, sacrospinous ligament fixation; ULS, uterosacral ligament suspension.

^a The analyses for each outcome of interest were performed on the modified intent-to-treat population, which includes all participants who were eligible, gave consent, were randomized to both the PMT and surgical interventions, and for whom the outcome was assessed (ie, nonmissing). For analyses assessing each outcome's change from baseline to a follow-up visit, all adjusted means, mean differences, SEs, 95% confidence intervals, and P values for outcomes were obtained from general linear models adjusting for randomized surgical intervention, randomized PMT intervention, visit, interaction between visit and randomized surgical intervention, interaction between visit and randomized PMT intervention, and 3-way interaction between visit and randomized surgical intervention and randomized PMT intervention, concomitant hysterectomy, age at surgical randomization, race (white, black, other), ethnicity, public insurance, and private insurance while controlling for a random surgeon effect (if found statistically significant) and repeated subject visits. All tests were conducted at a significance level of $P = .05$; ^b This adjusted P value corresponds to the test assessing whether there was a statistically significant change from baseline; ^c This adjusted P value corresponds to the test assessing whether there was a statistically significant difference in the outcome between the 2 surgical treatments; ^d The effect of surgery varies across the PMT groups and across visits ($P = .042$). See Table 4 for the effect of randomized surgical intervention within the PMT and non-PMT groups; ^e The effect of surgery varies across the PMT groups and across visits ($P = .011$). See Table 4 for the effect of randomized surgical intervention within the PMT and non-PMT groups.

Barber et al. Pain and activity after prolapse surgery. Am J Obstet Gynecol 2019.

FIGURE 3
Activity assessment scales, baseline to 3 months after surgery (unadjusted)**A**, Activity assessment scale total. **B**, Sedentary activities subscale. **C**, Ambulatory activities subscale. **D**, Work/exercise activities subscale.Barber et al. Pain and activity after prolapse surgery. *Am J Obstet Gynecol* 2019.

and 5.2%, respectively, with no differences between surgical groups. However, compared with SSLF, ULS resulted in lower odds of new or worsening buttock pain at 2 weeks (ULS, 14 of 185 [7.6%] vs SSLF, 43 of 181 [23.8%], [OR, 0.26, 95% CI, 0.13–0.52], $P < .001$) and 4–6 weeks (ULS, 8 of 173 [4.6%] vs SSLF, 18 of 171 [10.5%], [OR, 0.41, conservative 95% CI, 0.15–1.03], $P = .043$) after surgery and lesser odds of requiring narcotic medication for groin, leg, or buttock pain at 2 weeks (ULS, 12 of 182 (6.6%) vs SSLF, 26 of 180 (14.4%), [OR, 0.42, 95% CI, 0.19–0.90], $P = .017$).

At 4–6 weeks, no patient in the ULS group had groin, leg, or buttock pain requiring pain medications, while 8 of 167 in the SSLF (4.8%) did so ($P = .003$). Women in the SSLF group experienced more moderate to severe buttock pain at 2 weeks (ULS, 13 of 169 (7.7%) vs SSLF, 37 of 166 (22.3%), [OR, 0.29, 95% CI, 0.14–0.59], $P < .001$); at 4–6 weeks, this

difference was no longer statistically significant (3.6% vs 7.0%, $P = .216$).

Use of narcotic pain medications was reported by 14.3% of participants (46 of 322) prior to surgery, 53.7% (173 of 322) at 2, and 26.1% (84 of 322) at 4–6 weeks postoperatively. Thereafter, use was similar to baseline rates until 24 months when it decreased to 6.8% (22 of 322). Use of nonnarcotic pain medication was reported by 48.1% (152 of 316) prior to surgery, 68.7% (217 of 316) at 2 weeks, and similar to baseline at 3 months (45.3%, 143 of 316). Thereafter nonnarcotic use dropped steadily to 26.6% (84 of 316) at 2 years. There were no significant differences in narcotic or nonnarcotic use between surgical groups at any study time point.

Comment

Principal findings

Four to six weeks after native tissue transvaginal prolapse repair with

concomitant midurethral sling for stress urinary incontinence treatment, most women report pain levels below and functional activity levels above their baseline. Transient surgical pain in the immediate postoperative period is expected, with varying degrees reported in the literature.^{15–18} We found that pain improved as early as 4–6 weeks after surgery, including pain at rest, with normal activity, with exercise, and worst pain. Importantly, some improvements in pain were sustained throughout the 2 year study follow-up period.

Results

Although the perioperative pain patterns were similar in both surgical groups, there was one key difference: SSLF was associated with a greater odds of buttock pain compared with ULS. Compared with a prior report of 15% buttock pain at 6 weeks, we found a slightly lower rate of buttock pain (7.6% at 4–6 weeks)⁷;

TABLE 4

Activity assessment scales from baseline to 3 months after surgery in PMT and non-PMT groups modeling outcome as change from baseline^a

Variable	Time frame	PMT group						Non-PMT group					
		ULS surgical treatment (n = 90)		SSLF surgical treatment (n = 95)		Surgical treatment difference		ULS surgical treatment (n = 97)		SSLF surgical treatment (n = 91)		Surgical treatment difference	
		Estimate	Adjusted Pvalue ^b	Estimate	Adjusted Pvalue ^b	Adjusted mean difference (95% CI) ^c	Adjusted Pvalue ^c	Estimate	Adjusted Pvalue ^b	Estimate	Adjusted Pvalue ^b	Adjusted mean difference (95% CI) ^c	Adjusted Pvalue ^c
Overall AAS score													
	Baseline	79.66 (2.33, 89)	—	76.94 (2.31, 94)	—	2.72 (−2.13, 7.56)	.271	76.55 (2.36, 96)	—	78.97 (2.38, 91)	—	−2.42 (−7.24, 2.40)	.324
	Baseline	38 to 100		25 to 100				25 to 100		38 to 100			
	2 week change	3.03 (2.63, 83)	.250	−1.67 (2.62, 87)	.525	4.70 (−1.11, 10.51)	.113	1.92 (2.65, 87)	.470	−4.48 (2.66, 87)	.094	6.40 (0.64, 12.15)	.029
	2 week change	−62 to 56		−77 to 50				−74 to 73		−77 to 54			
	4–6 week change	7.66 (2.61, 88)	.004	10.14 (2.59, 92)	< .001	−2.48 (−8.20, 3.25)	.396	11.79 (2.62, 94)	< .001	7.39 (2.65, 90)	.006	4.41 (−1.27, 10.09)	.128
	4–6 week change	−51 to 56		−50 to 50				−39 to 73		−53 to 54			
	3 month change	10.89 (2.65, 81)	< .001	15.69 (2.64, 82)	< .001	−4.80 (−10.67, 1.07)	.109	17.33 (2.66, 87)	< .001	11.26 (2.69, 82)	< .001	6.07 (0.27, 11.88)	.040
	3 month change	−42 to 56		−42 to 58				−10 to 63		−34 to 54			

Barber et al. Pain and activity after prolapse surgery. Am J Obstet Gynecol 2019.

(continued)

TABLE 4
Activity assessment scales from baseline to 3 months after surgery in PMT and non-PMT groups modeling outcome as change from baseline^a (continued)

Variable	Time frame	PMT group						Non-PMT group					
		ULS surgical treatment (n = 90)		SSLF surgical treatment (n = 95)		Surgical treatment difference		ULS surgical treatment (n = 97)		SSLF surgical treatment (n = 91)		Surgical treatment difference	
		Estimate	Adjusted Pvalue ^b	Estimate	Adjusted Pvalue ^b	Adjusted mean difference (95% CI) ^c	Adjusted Pvalue ^c	Estimate	Adjusted Pvalue ^b	Estimate	Adjusted Pvalue ^b	Adjusted mean difference (95% CI) ^c	Adjusted Pvalue ^c
Sedentary Activities Scale													
	Baseline	30.86 (0.83, 89)	—	29.86 (0.82, 94)	—	1.00 (−0.73, 2.72)	.256	29.84 (0.84, 96)	—	31.08 (0.85, 91)	—	−1.24 (−2.95, 0.48)	.157
	Baseline	14 to 36		9 to 36		9 to 36		16 to 36					
	2 week change	−0.45 (0.96, 85)	.640	−2.77 (0.95, 90)	.004	2.32 (0.20, 4.44)	.032	−0.51 (0.96, 92)	.597	−3.42 (0.97, 88)	.001	2.91 (0.81, 5.01)	.007
	2 week change	−25 to 23		−25 to 18		−30 to 27		−23 to 11					
	4–6 week change	1.74 (0.96, 88)	.069	2.92 (0.95, 93)	.002	−1.17 (−3.27, 0.93)	.273	3.34 (0.96, 94)	.001	1.09 (0.97, 90)	.263	2.26 (0.17, 4.34)	.034
	4–6 week change	−18 to 23		−14 to 23		−14 to 27		−20 to 16					
	3 month change	2.75 (0.97, 81)	.005	4.38 (0.96, 84)	< .001	−1.63 (−3.78, 0.52)	0.138	5.25 (0.98, 87)	< .001	2.37 (0.98, 84)	.017	2.88 (0.75, 5.01)	.008
	3 month change	−18 to 23		−14 to 23		−7 to 27		−18 to 16					

AAS, Ambulatory Activities Scale; CI, confidence interval; PMT, pelvic floor muscle training; SSLF, sacrospinous ligament fixation; ULS, uterosacral ligament suspension.

^a The analyses for each outcome of interest were performed on the modified intent-to-treat population, which includes all participants who were eligible, gave consent, were randomized to both the PMT and surgical interventions, and for whom the outcome was assessed (ie, nonmissing). For analyses assessing each outcome's change from baseline to a follow-up visit, all adjusted means, mean differences, SEs, 95% confidence intervals, and P values for outcomes were obtained from general linear models adjusting for randomized surgical intervention, randomized PMT intervention, visit, interaction between visit and randomized surgical intervention, interaction between visit and randomized PMT intervention, and 3-way interaction between visit and randomized surgical intervention and randomized PMT intervention, concomitant hysterectomy, age at surgical randomization, race (white, black, other), ethnicity, public insurance, and private insurance while controlling for a random surgeon effect (if found statistically significant) and repeated subject visits. All tests were conducted at a significance level of $P = .05$; ^b This adjusted P value corresponds to the test assessing whether there was a statistically significant change from baseline; ^c This adjusted P value corresponds to the test assessing whether there was a statistically significant difference in the outcome between the 2 surgical treatments.

Barber et al. Pain and activity after prolapse surgery. Am J Obstet Gynecol 2019.


TABLE 5
Long-term pain and activity after surgery SF36 scale changes from baseline to 3 months after surgery modeling outcome as change from baseline^a

Variable	Time frame	Statistic	All surgical treatments (n = 374)		ULS surgical treatment (n = 188)		SSLF surgical treatment (n = 186)		Surgical treatment difference	
			Estimate	Adjusted Pvalue ^b	Estimate	Adjusted Pvalue ^b	Estimate	Adjusted Pvalue ^b	Adjusted mean difference (95% CI) ^c	Adjusted Pvalue ^c
SF-36 Bodily Pain Scale^d										
	Baseline	Adjusted mean (SE, n)	43.20 (1.28, 361)	—	43.70 (1.39, 179)	—	42.70 (1.42, 182)	—	1.00 (−1.24, 3.25)	.381
	6 month change	Adjusted mean (SE, n)	6.72 (1.34, 332)	< .001	7.20 (1.46, 165)	< .001	6.23 (1.49, 167)	< .001	0.97 (−1.47, 3.41)	.436
	12 month change	Adjusted mean (SE, n)	6.80 (1.34, 320)	< .001	6.65 (1.46, 161)	< .001	6.95 (1.50, 159)	< .001	−0.30 (−2.77, 2.17)	.812
	24 month change	Adjusted mean (SE, n)	5.62 (1.35, 298)	< .001	5.47 (1.48, 149)	< .001	5.77 (1.51, 149)	< .001	−0.31 (−2.84, 2.23)	.812
SF-36 Physical Functioning Scale^d										
	Baseline	Adjusted mean (SE, n)	39.02 (1.14, 365)	—	39.45 (1.25, 182)	—	38.59 (1.28, 183)	—	0.86 (−1.30, 3.03)	.434
	6 month change	Adjusted mean (SE, n)	5.60 (1.11, 337)	< .001	5.58 (1.24, 168)	< .001	5.61 (1.27, 169)	< .001	−0.03 (−2.33, 2.27)	.979
	12 month change	Adjusted mean (SE, n)	5.96 (1.11, 322)	< .001	6.05 (1.24, 162)	< .001	5.86 (1.28, 160)	< .001	0.19 (−2.13, 2.51)	.875
	24 month change	Adjusted mean (SE, n)	5.79 (1.12, 301)	< .001	5.53 (1.25, 151)	< .001	6.05 (1.29, 150)	< .001	−0.52 (−2.88, 1.84)	.668
SF-36 Role Physical Scale^d										
	Baseline	Adjusted mean (SE, n)	41.40 (1.18, 364)	—	41.44 (1.30, 182)	—	41.35 (1.33, 182)	—	0.09 (−2.16, 2.34)	.939
	6 month change	Adjusted mean (SE, n)	4.70 (1.11, 336)	< .001	5.25 (1.24, 168)	< .001	4.16 (1.27, 168)	.001	1.09 (−1.24, 3.41)	.360
	12 month change	Adjusted mean (SE, n)	5.26 (1.11, 321)	< .001	5.63 (1.24, 163)	< .001	4.89 (1.29, 158)	< .001	0.74 (−1.61, 3.09)	.537
	24 month change	Adjusted mean (SE, n)	4.72 (1.12, 300)	< .001	4.62 (1.26, 150)	< .001	4.83 (1.29, 150)	< .001	−0.21 (−2.61, 2.19)	.862

CI, confidence interval; SF-36, MOS 36-item Short-Form Health Survey; SSLF, sacrospinous ligament fixation; ULS, uterosacral ligament suspension.

^a The analyses for each outcome of interest were performed on the modified intent-to-treat population, which includes all participants who were eligible, gave consent, were randomized to both the PMT and surgical interventions, and for whom the outcome was assessed (ie, nonmissing). All analyses are performed as intent-to-treat analyses, and therefore, each outcome will be compared across each participant's randomized surgical intervention. In addition, analyses were performed assessing each outcome's change from baseline to follow-up visit. All adjusted means, mean differences, SEs, 95% confidence intervals, and P values for outcomes were obtained from general linear models adjusting for randomized surgical intervention, randomized PMT intervention, visit, all pairwise interactions between visit and the 2 randomized interventions, 3-way interaction between visit and the 2 randomized interventions, concomitant hysterectomy, age at surgical randomization, race (white, black, other), ethnicity, public insurance, and private insurance while controlling for a random surgeon effect (if found statistically significant) and repeated subject visits. All tests were conducted at a significance level of $P = .05$; ^b This adjusted P value corresponds to the test assessing whether there was a statistically significant change from baseline; ^c This adjusted P value corresponds to the test assessing whether there was a statistically significant difference in the outcome between the 2 surgical treatments; ^d For the SF-36 scales, higher scores indicate better functioning and/or less pain.

Barber et al. Pain and activity after prolapse surgery. Am J Obstet Gynecol 2019.

FIGURE 4
Long-term pain and activity after surgery

SF-36 scale changes from baseline to 3 months after surgery modeling outcome as change from baseline are shown. (The analyses for each outcome of interest were performed on the modified intent-to-treat population, which includes all participants who were eligible, gave consent, were randomized to both the pelvic floor muscle training [PMT] and surgical interventions, and for whom the outcome was assessed (ie, nonmissing). For analyses assessing each outcome's change from baseline to a follow-up visit, all adjusted means, mean differences, SEs, 95% confidence intervals, and *P* values for outcomes were obtained from general linear models adjusting for randomized surgical intervention, randomized PMT intervention, visit, interaction between visit and randomized surgical intervention, interaction between visit and randomized PMT intervention, and 3-way interaction between visit and randomized surgical intervention and randomized PMT intervention, concomitant hysterectomy, age at surgical randomization, race [white, black, other], ethnicity, public insurance, and private insurance while controlling for a random surgeon effect [if found statistically significant] and repeated subject visits. All tests were conducted at a significance level of $P = .05$.) **A**, SF-36 bodily pain scale change from baseline across visits by surgical interventions. **B**, SF-36 physical functioning scale change from baseline across visits by surgical interventions. **C**, SF-36 role physical scale change from baseline across visits by surgical interventions.

SF-36, MOS 36-item Short-Form Health Survey.

Barber et al. Pain and activity after prolapse surgery. *Am J Obstet Gynecol* 2019.

this difference may be related to our definition of only new or worsening buttock pain.

Several of our findings suggest that there may be a pain control benefit to perioperative PMT in women undergoing ULS. For instance, at 3 months participants randomized to ULS with PMT reported better improvement in pain at rest. In this study, we did not inquire specifically about groin, leg/thigh, or buttocks pain after the 4–6 week postoperative questionnaire; while the rate was lower at 4–6 weeks than at 2 weeks,

we do not know the long-term trajectory. A larger sample would be required to investigate the impact of persistent buttock pain on long-term functional activity.

The proportion of women who took prescribed narcotic pain medication reflects the prescribing practices during this study. We do not know the indication for which women took pain medication prior to surgery. The relatively high use of pain medication at baseline in our cohort may be associated with conditions other than pelvic organ

prolapse, such as painful joints or chronic low back pain, conditions that are associated both with pain medication use and is also common in older women who are at risk for pelvic floor disorders.

It has also been shown that women who undergo surgery for prolapse are more likely to report a history of heavy work than women without prolapse, which could also be associated with back and joint pain requiring pain medications use.¹⁹ A recent study found that in women who underwent minimally invasive urogynecological procedures,

baseline chronic pain was a risk factor for higher rates of postoperative narcotic pain medication use; however, on average, patients used only one third of the narcotics prescribed.²⁰ In our surgical cohort, self-reported narcotic pain medication use returned to approximately baseline (14.3%) by 3 months after surgery (17.7%), with a further reduction to 6.8% at 2 years, suggesting that the surgical intervention did not increase, and may have decreased, long-term narcotic use.

Clinical and research implications

Most clinicians do not consider pain to be a major symptom of pelvic organ prolapse. We found it intriguing that reports of pain levels fell below a relatively low pain level at baseline, suggesting that there may be a mild sensation that affected patients interpret as pain, that is effectively resolved with native tissue vaginal repair. The reduced pain seen at 4–6 weeks and 3 months postoperatively by surgical pain scales support this possibility. Additional studies to evaluate any associations between pain and pelvic organ prolapse may further refine this relationship.

Beyond perioperative pain control, functional activity and resumption of usual activities play an important role in patient satisfaction. Significant and clinically meaningful improvements from baseline were seen in the SF-36 Bodily Pain Scale, Physical Functioning Scale and Role-Physical Scale in our analysis.

Our findings are consistent with prior reports. Whiteside et al²¹ reported that patients with activity-related goals preferred surgery and that postoperative activity improved overall and for each subscale of the Activity Assessment Scale. In a prospective cohort of women undergoing sacrocolpopexy for apical prolapse, at 1 year one third of the women reported increased exercise intensity and most reported that prolapse no longer interfered with activities.²² In a comparison of obliterative vs reconstructive procedures for prolapse in women 65 years old or older, similar significant and clinically important improvements in the bodily pain and social functioning were also noted.²³

Strengths and limitations

The strengths of this study are that it is an analysis of a large, multicentered randomized clinical trial. The study population is well characterized and validated instruments were used pre- and postoperatively to assess pain and activity outcomes.

Participants and outcome assessors were masked to surgical treatment assignment. This is a significant strength over most other studies comparing surgical procedures for pelvic organ prolapse; however, it is possible that some participants may have become unmasked based on their postoperative experience (ie, unilateral buttock pain).

Much of the existing literature on pain and functional activity after pelvic organ prolapse surgery focuses on the immediate postoperative period, and there is a lack of consistent methods used for evaluating perioperative pain and activity. This study includes the use of Surgical Pain Scales and Activity Assessment Scales that provide more detailed information about the circumstances under which pain is experienced and specifically characterizes various activities.

All patients received standardized postoperative instructions that included limiting heavy lifting or exercise; however, we have no information on compliance with those instructions or how these standardized instructions may have had an impact on postoperative pain or functional activity. Pain medication use by participants' self-report is also a study limitation.

Conclusions

In conclusion, pain and functional activity improve for up to 2 years after native tissue reconstructive surgery with uterosacral or sacrospinous vaginal vault suspension and midurethral sling for stages 2–4 pelvic organ prolapse. Additionally, on average, immediate postoperative pain is low and improves to below baseline levels by 4–6 weeks. The course of postoperative pain and activity following vaginal reconstructive surgery with concomitant midurethral sling is reassuring.

We would anticipate further improvements to this favorable course with

less opioid prescribing, consistent with improvements in patient care seen broadly since our study was initiated. As the oldest minimally invasive route of reconstruction for pelvic organ prolapse, this evidence bolsters the well-deserved reputation of this minimally morbid approach and highlights benefits of treatment of coexisting prolapse and stress urinary incontinence, reducing pain and improving functional activity more than previously recognized. ■

Acknowledgments

This trial is registered at clinicaltrials.gov under Registration number NCT00597935. Investigators include the following: Cleveland Clinic, Cleveland OH, Anna Frick, MD, John Eric Jelovsek, MD, Betsy O'Dougherty, Marie F. R. Paraiso, MD, Ly Pung, RN, Beri M. Ridgeway, MD, and Cheryl Williams; Duke University, Durham NC, Cindy L. Amundsen, MD, Ingrid Harm-Ernandes, Mary Raynor, Nazema Y Siddiqui, MD, Anthony G. Visco, MD, Alison C. Weidner, MD, and Jennifer M. Wu, MD; Kaiser Permanente—Downey, John Nguyen, MD; Kaiser Permanente—Bellflower, Sharon Jakus-Waldman, MD; Kaiser Permanente—San Diego, Gouri Diwadkar, MD, Lynn M. Hall, Linda M, Mackinnon, Shawn A. Meneffee, MD, Jasmine Tan-Kim, MD, and Gisselle Zazueta-Damian; Loyola University, Chicago, IL, Elizabeth Mueller, MD, and Mary Tulke; University of Pittsburgh, Magee-Womens Research Institute, Diane Borello-France; RTI International, Research Triangle Park, NC, Lauren Klein Warren, Daryl Matthews, Amanda Shaffer, Tamara T. Terry, Jutta Thornberry, Dennis Wallace, Ryan E. Whitworth, and Kevin A Wilson; Vanderbilt University, Nashville, TN, Katherine Hartmann, MD; University of Alabama at Birmingham, Alicia Ballard, Julie Burge, Kathryn L. Burgio, PhD, Kathy Carter, Patricia S. Goode, MD, Alayne D. Markland, MD, Lisa S. Pair, Candace Parker-Autry, MD, Holly E. Richter, PhD, MD, R. Edward Varner, MD, and Tracey S. Wilson; University of California, San Diego, Michael E. Albo, MD, Cara Grimes, MD, Emily S Lukacz, MD, and Charles W. Nager, MD; University of Michigan, Ann Arbor, MI, Yang Wang Casher, Yeh-Hsin Chen, Donna DiFranco, Bev Marchant, Cathie Spino, and John T. Wei, MD; University of Utah Medical Center, Salt Lake City, UT, Jan Baker, Yvonne Hsu, Maria Masters, and Amy Orr; University of Texas—Southwestern, Dallas TX, Shanna Atnip, Elva Kelly Moore, David Rahn, MD, and Joseph Schaffer, MD; Northwest Texas Physician Group, Amarillo, TX, Susan F. Meikle, MD. The Pelvic Floor Disorders Network Data Safety and Monitoring Board members are as follows: Kay Dickersin, Johns Hopkins Bloomberg School of Public Health; Luohua Jiang, Texas A&M Health Science University; Missy Lavender, Women's Health

Foundation; Kate O'Dell, UMass Memorial Medical Center; Kate Ryan, National Women's Health Network; Paul Tulikangas, University of Connecticut Hartford Hospital; Lan Kong, Penn State University College of Medicine; Donna McClish, Virginia Commonwealth University; Leslie Rickey, Yale New Haven Hospital; David Shade, Johns Hopkins University; Ashok Tuteja, University of Utah; and Susan Yount, Frontier Nursing University, Lexington KY.

References

1. Wu JM, Matthews CA, Conover MM, Pate V, Jonsson Funk M. Lifetime risk of stress urinary incontinence or pelvic organ prolapse surgery. *Obstet Gynecol* 2014;123:1201–6.
2. Food and Drug Administration. Urogynecologic surgical mesh:update on the safety and effectiveness of transvaginal mesh placement for pelvic organ prolapse, 2011. Rockville (MD): Food and Drug Administration; 2011.
3. Boyles SH, Weber AM, Meyn L. Procedures for pelvic organ prolapse in the United States, 1979–1997. *Am J Obstet Gynecol* 2003;188:108–15.
4. Brown JS, Waetjen LE, Subak LL, Thom DH, Van den Eeden S, Vittinghoff E. Pelvic organ prolapse surgery in the United States, 1997. *Am J Obstet Gynecol* 2002;186:712–6.
5. Olsen AL, Smith VJ, Bergstrom JO, Colling JC, Clark AL. Epidemiology of surgically managed pelvic organ prolapse and urinary incontinence. *Obstet Gynecol* 1997;89:501–6.
6. Maher C, Feiner B, Baessler K, Schmid C. Surgical management of pelvic organ prolapse in women. *Cochrane Database Syst Rev* 2013;4:CD004014.
7. Unger CA, Walters MD. Gluteal and posterior thigh pain in the postoperative period and the need for intervention after sacrospinous ligament colpopexy. *Female Pelvic Med Reconstr Surg* 2014;20:208–11.
8. Barber MD, Brubaker L, Burgio KL, et al. Comparison of 2 transvaginal surgical approaches and perioperative behavioral therapy for apical vaginal prolapse: the OPTIMAL randomized trial. *JAMA* 2014;311:1023–34.
9. Lowenstein L, Dooley Y, Kenton K, Mueller E, Brubaker L. Neural pain after uterosacral ligament vaginal suspension. *Int Urogynecol J Pelvic Floor Dysfunct* 2007;18:109–10.
10. Chung CP, Kuehl TJ, Larsen WI, Yandell PM, Shull BL. Recognition and management of nerve entrapment pain after uterosacral ligament suspension. *Obstet Gynecol* 2012;120:292–5.
11. Barber MD, Brubaker L, Menefee S, et al. Operations and pelvic muscle training in the management of apical support loss (OPTIMAL) trial: design and methods. *Contemp Clin Trials* 2009;30:178–89.
12. Barber MD, Kenton K, Janz NK, et al. Validation of the activities assessment scale in women undergoing pelvic reconstructive surgery. *Female Pelvic Med Reconstr Surg* 2012;18:205–10.
13. Barber MD, Janz N, Kenton K, et al. Validation of the surgical pain scales in women undergoing pelvic reconstructive surgery. *Female Pelvic Med Reconstr Surg* 2012;18:198–204.
14. Ware JE Jr, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36). I. Conceptual framework and item selection. *Med Care* 1992;30:473–83.
15. Anger JT, Mueller ER, Tarnay C, et al. Robotic compared with laparoscopic sacrocolpopexy: a randomized controlled trial. *Obstet Gynecol* 2014;123:5–12.
16. Shatkin-Margolis A, Crisp CC, Morrison C, Pauls RN. Predicting pain levels following vaginal reconstructive surgery: who is at highest risk? *Female Pelvic Med Reconstr Surg* 2018;24:172–5.
17. Willis-Gray MG, Husk KE, Brueseke TJ, Wu JM, Dieter AA. Predictors of opioid administration in the acute postoperative period. *Female Pelvic Med Reconstr Surg* 2018 Feb 27. <https://doi.org/10.1097/SPV.0000000000000567>. [Epub ahead of print].
18. Botros C, Letko J, Gafni-Kane A, Botros S, Lozo S, Sand P. Postoperative pain and perceptions of recuperation after suture- and mesh-based apical sacrospinous ligament suspension. *Int J Gynaecol Obstet* 2017;139:95–9.
19. Nygaard IE, Shaw JM. Physical activity and the pelvic floor. *Am J Obstet Gynecol* 2016;214:164–71.
20. Swenson CW, Kelley AS, Fenner DE, Berger MB. Outpatient narcotic use after minimally invasive urogynecologic surgery. *Female Pelvic Med Reconstr Surg* 2016;22:377–81.
21. Whiteside JL, Johnson JD, Spratt KF. Goals, symptoms, signs, and treatments among women with pelvic floor disorders. *Female Pelvic Med Reconstr Surg* 2014;20:104–10.
22. Nygaard I, Handa VL, Brubaker L, et al. Changes in physical activity after abdominal sacrocolpopexy for advanced pelvic organ prolapse. *Am J Obstet Gynecol* 2008;198:570.e1–5.
23. Barber MD, Amundsen CL, Paraiso MF, Weidner AC, Romero A, Walters MD. Quality of life after surgery for advanced pelvic organ prolapse in elderly women: obliterative and reconstructive vaginal surgery. *Int Urogynecol J* 2007;18:799–806.

Author and article information

From the Department of Obstetrics and Gynecology, Duke University Medical Center, Durham NC (Dr Barber); the Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California—San Diego, San Diego CA (Dr Brubaker); the Department of Obstetrics and Gynecology, University of Utah, Salt Lake City, UT (Dr Nygaard); the Department of Obstetrics and Gynecology, University of Texas—Southwestern, Dallas TX (Dr Wai); the Department of Obstetrics and Gynecology, Kaiser Permanente, San Diego, CA (Dr Dyer); the Department of Obstetrics and Gynecology, University of Alabama—Birmingham, Birmingham AL (Dr Ellington); and the Department of Social, Statistical, and Environmental Sciences, RTI International, Research Triangle Park, NC (Dr Gantz and Mr Sridhar).

Received March 20, 2019; revised June 5, 2019; accepted June 6, 2019.

This study was supported by grants from the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the National Institutes of Health Office of Research on Women's Health (2 UG1 HD041261-16, 2 UG1 HD054214, 2 UG1 HD041267-17, 2 UG1 HD054241, 2 U24 HD069031, U01 HD041249, U10 HD041250, U10 HD041261, U10 HD041267, U10 HD054136, U10 HD054214, U10 HD054215, U01 HD069031, and U10 HD054241).

Dr Barber received royalties from Elsevier and UpToDate; Dr Brubaker received editorial stipends from the *Journal of the American Medical Association*, the *Female Pelvic Medicine and Reconstructive Surgery* journal, and UpToDate, and honorarium from the American Board of Obstetrics and Gynecology; Dr Dyer received research funding from Pelvalon, Sunnyvale, CA; Dr Nygaard received an editorial stipend from Elsevier; Dr Gantz received research funding from Boston Scientific on behalf of the Eunice Kennedy Shriver National Institute of Child Health and Human Development Pelvic Floor Disorders Network; the other authors report no conflict of interest.

Corresponding author: Matthew D. Barber, MD, MHS. matthew.barber@duke.edu